Published in Proc Natl Acad Sci U S A on January 16, 2008
Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science (2015) 2.20
PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal (2010) 2.08
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet (2009) 1.88
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol (2010) 1.34
Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res (2010) 1.33
Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat (2011) 1.31
Molecular pathways: radiation-induced cognitive impairment. Clin Cancer Res (2013) 1.28
Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro. Cell Cycle (2012) 1.23
Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism. PLoS One (2011) 1.22
EET signaling in cancer. Cancer Metastasis Rev (2011) 1.18
ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro. Mol Cancer (2010) 1.15
The PPARalpha agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation. Int J Radiat Oncol Biol Phys (2009) 1.13
Radiation-induced cognitive impairment--from bench to bedside. Neuro Oncol (2012) 1.08
Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci U S A (2013) 1.08
The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. J Biol Chem (2010) 1.03
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer (2013) 1.01
Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol (2014) 0.99
The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Arch Biochem Biophys (2009) 0.98
PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res (2008) 0.96
Peroxisome proliferator activated receptor α ligands as anticancer drugs targeting mitochondrial metabolism. Curr Pharm Biotechnol (2013) 0.95
Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol (2010) 0.94
Activation of peroxisome proliferator-activated receptor α (PPARα) suppresses hypoxia-inducible factor-1α (HIF-1α) signaling in cancer cells. J Biol Chem (2012) 0.93
The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harb Perspect Med (2012) 0.93
Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis. PPAR Res (2008) 0.93
Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Transl Oncol (2011) 0.92
Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarked by reduced dependence on exogenous glutamine. J Biol Chem (2015) 0.91
An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes (2013) 0.90
PPARalpha Ligands as Antitumorigenic and Antiangiogenic Agents. PPAR Res (2008) 0.90
Targeting Nuclear Hormone Receptors: PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis. Int J Rheumatol (2011) 0.88
Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products. Wiley Interdiscip Rev Syst Biol Med (2010) 0.88
The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. Biochim Biophys Acta (2013) 0.87
Nuclear receptors as modulators of the tumor microenvironment. Cancer Prev Res (Phila) (2011) 0.87
PPARα activation can help prevent and treat non-small cell lung cancer. Cancer Res (2013) 0.87
Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key? PPAR Res (2008) 0.87
Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway. Oncotarget (2014) 0.87
Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells. PLoS One (2013) 0.86
Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth. PPAR Res (2008) 0.85
The peroxisomal proliferator-activated receptor (PPAR) α agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairment. Radiat Res (2014) 0.84
Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway. BMC Cancer (2014) 0.84
Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats. Int J Pept (2012) 0.83
Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes. PPAR Res (2010) 0.83
Macrophages, PPARs, and Cancer. PPAR Res (2008) 0.83
PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials. PPAR Res (2012) 0.83
NF-κB/RelA-PKM2 mediates inhibition of glycolysis by fenofibrate in glioblastoma cells. Oncotarget (2015) 0.82
Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death. Mol Cell Biol (2014) 0.81
The Role of PPARs in the Endothelium: Implications for Cancer Therapy. PPAR Res (2008) 0.81
PPARα modulates gene expression profiles of mitochondrial energy metabolism in oral tumorigenesis. Biomedicine (Taipei) (2016) 0.81
Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer. ScientificWorldJournal (2015) 0.80
Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy. Diabetes (2013) 0.79
PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma. PPAR Res (2012) 0.79
The peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice. Int J Mol Sci (2014) 0.78
Regulation of vascular endothelial growth factor by metabolic context of the cell. Glycoconj J (2014) 0.78
Interactions of PPAR-alpha and adenosine receptors in hypoxia-induced angiogenesis. Vascul Pharmacol (2013) 0.78
Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis. Cancers (Basel) (2012) 0.78
A comparison of peroxisome proliferator-activated receptor-α agonist and antagonist on human umbilical vein endothelial cells angiogenesis. Adv Biomed Res (2013) 0.78
Fenofibrate inhibits the expression of VEGFC and VEGFR-3 in retinal pigmental epithelial cells exposed to hypoxia. Exp Ther Med (2015) 0.78
Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. Pharmaceuticals (Basel) (2010) 0.78
Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes. Diabetes Metab Syndr Obes (2009) 0.77
PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes. PPAR Res (2008) 0.77
Metabolic Reprogramming in Glioma. Front Cell Dev Biol (2017) 0.77
Anti-tumoral effects of miR-3189-3p in glioblastoma. J Biol Chem (2015) 0.76
AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells. PPAR Res (2012) 0.76
Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats. PLoS One (2014) 0.76
Effects of PPARα inhibition in head and neck paraganglioma cells. PLoS One (2017) 0.75
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. Front Endocrinol (Lausanne) (2017) 0.75
The molecular mechanisms of action of PPAR-γ agonists in the treatment of corneal alkali burns (Review). Int J Mol Med (2016) 0.75
PPARα, a predictor of patient survival in glioma, inhibits cell growth through the E2F1/miR-19a feedback loop. Oncotarget (2016) 0.75
Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing. Oncotarget (2017) 0.75
Stimulating effect of normal-dosing of fibrates on cell proliferation: word of warning. Lipids Health Dis (2016) 0.75
Clinical research of fenofibrate and spironolactone for acute central serous chorioretinopathy. Int J Ophthalmol (2016) 0.75
Myocardial capillary density in normal and diabetic male rats: Effect of bezafibrate. Res Pharm Sci (2013) 0.75
Role of peroxisome proliferator-activated receptor alpha and gamma in antiangiogenic effect of pomegranate peel extract. Iran J Basic Med Sci (2016) 0.75
PPAR Agonists for the Prevention and Treatment of Lung Cancer. PPAR Res (2017) 0.75
Reverse Translational Study of Fenofibrate's Observed Effects in Diabetes-Associated Retinopathy. Clin Transl Sci (2016) 0.75
Gold nanoparticles functionalized with peptides for specific affinity aggregation assays of estrogen receptors and their agonists. Sensors (Basel) (2012) 0.75
Cyclin D1 represses peroxisome proliferator-activated receptor alpha and inhibits fatty acid oxidation. Oncotarget (2016) 0.75
Fenofibrate Suppresses Oral Tumorigenesis via Reprogramming Metabolic Processes: Potential Drug Repurposing for Oral Cancer. Int J Biol Sci (2016) 0.75
Inflammation and cancer. Nature (2002) 53.78
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
The mechanisms of action of PPARs. Annu Rev Med (2002) 6.71
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
The PPARs: from orphan receptors to drug discovery. J Med Chem (2000) 5.29
The PPARalpha-leukotriene B4 pathway to inflammation control. Nature (1996) 5.14
Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation (1999) 3.53
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest (2006) 3.48
Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer (2004) 2.93
Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis (1997) 2.46
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol (2002) 2.26
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol (2005) 2.14
PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation (1999) 2.02
Endostatin's antiangiogenic signaling network. Mol Cell (2004) 1.95
PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest (2001) 1.82
Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res (2001) 1.80
Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther (2005) 1.77
Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol (2006) 1.74
Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res (2006) 1.49
Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog (2002) 1.43
Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res (2003) 1.38
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem (2002) 1.36
PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res (2003) 1.33
Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. J Biol Chem (2007) 1.30
PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun (2002) 1.27
PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One (2007) 1.24
In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer (2006) 1.21
Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther (2007) 1.16
Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci (2003) 1.12
Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res (2004) 1.08
Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res (2001) 1.07
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol (2001) 1.04
An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int J Cancer (2004) 1.03
Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res (2000) 1.02
Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion. Mol Carcinog (2000) 0.93
Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. Atherosclerosis (2005) 0.92
Melanoma chemoprevention: a role for statins or fibrates? Am J Ther (2003) 0.84
Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature (2008) 7.60
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst (2002) 3.77
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res (2007) 3.53
Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood (2007) 3.38
Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle (2006) 3.10
Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A (2003) 3.10
Gene Expression Dynamics Inspector (GEDI): for integrative analysis of expression profiles. Bioinformatics (2003) 2.92
Non-genetic heterogeneity--a mutation-independent driving force for the somatic evolution of tumours. Nat Rev Genet (2009) 2.69
Platelets actively sequester angiogenesis regulators. Blood (2008) 2.47
High-betweenness proteins in the yeast protein interaction network. J Biomed Biotechnol (2005) 2.44
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol (2005) 2.14
Alteration of nuclear lamin organization inhibits RNA polymerase II-dependent transcription. J Cell Biol (2002) 2.14
Control of basement membrane remodeling and epithelial branching morphogenesis in embryonic lung by Rho and cytoskeletal tension. Dev Dyn (2005) 2.13
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol (2002) 2.10
Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature (2008) 2.09
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A (2006) 2.09
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2012) 2.04
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res (2009) 2.04
Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest (2004) 2.03
Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1/S transition. J Biol Chem (2004) 1.98
Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A (2004) 1.98
Endostatin's antiangiogenic signaling network. Mol Cell (2004) 1.95
Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol (2008) 1.93
Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol (2008) 1.92
Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer (2011) 1.91
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res (2009) 1.90
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr (2009) 1.89
Condensed mitotic chromatin is accessible to transcription factors and chromatin structural proteins. J Cell Biol (2004) 1.86
Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol (2007) 1.84
Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol (2009) 1.83
Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood (2010) 1.81
Vacuum-assisted closure: microdeformations of wounds and cell proliferation. Plast Reconstr Surg (2004) 1.81
TBP dynamics in living human cells: constitutive association of TBP with mitotic chromosomes. Mol Biol Cell (2002) 1.78
The potential landscape of genetic circuits imposes the arrow of time in stem cell differentiation. Biophys J (2010) 1.76
Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer (2010) 1.76
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics (2005) 1.72
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med (2004) 1.70
The mechanism of action of the vacuum-assisted closure device. Plast Reconstr Surg (2008) 1.68
Understanding gene circuits at cell-fate branch points for rational cell reprogramming. Trends Genet (2010) 1.67
Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics (2007) 1.67
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res (2013) 1.64
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology (2013) 1.62
Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics (2006) 1.60
Differentiation-induced colocalization of the KH-type splicing regulatory protein with polypyrimidine tract binding protein and the c-src pre-mRNA. Mol Biol Cell (2003) 1.60
Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding. Ann Surg (2005) 1.59
Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood (2009) 1.57
Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat (2010) 1.57
Multistable and multistep dynamics in neutrophil differentiation. BMC Cell Biol (2006) 1.56
Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood (2006) 1.53
Noise-driven stem cell and progenitor population dynamics. PLoS One (2008) 1.52
Filamin links cell shape and cytoskeletal structure to Rho regulation by controlling accumulation of p190RhoGAP in lipid rafts. J Cell Sci (2007) 1.51
Medusa structure of the gene regulatory network: dominance of transcription factors in cancer subtype classification. Exp Biol Med (Maywood) (2011) 1.50
Gene-pair expression signatures reveal lineage control. Nat Methods (2013) 1.49
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther (2008) 1.47
Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem (2007) 1.46
Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J (2008) 1.46
Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med (2006) 1.42
Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res (2004) 1.42
The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study. J Pediatr Surg (2005) 1.39
Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis (2008) 1.38
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell (2005) 1.37
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev (2010) 1.36
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol (2007) 1.34
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res (2005) 1.33
Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res (2005) 1.33
Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res (2005) 1.33
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A (2013) 1.33
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol (2008) 1.33
Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat (2011) 1.31
RNA polymerase III transcripts and the PTB protein are essential for the integrity of the perinucleolar compartment. Mol Biol Cell (2003) 1.30